Misplaced Pages

Metabolic syndrome
Other names	Dysmetabolic syndrome X
A man with marked central obesity, a hallmark of metabolic syndrome. His weight is 182 kg (400 lbs), height 185 cm (6 ft 1 in), and body mass index (BMI) 53 (normal 18.5 to 25).
Specialty	Endocrinology
Symptoms	Obesity
Differential diagnosis	Insulin resistance, prediabetes, hyperuricemia, obesity, nonalcoholic fatty liver disease, polycystic ovarian syndrome, erectile dysfunction, acanthosis nigricans

Metabolic syndrome is a clustering of at least three of the following five medical conditions: abdominal obesity, high blood pressure, high blood sugar, high serum triglycerides, and low serum high-density lipoprotein (HDL).

Metabolic syndrome is associated with the risk of developing cardiovascular disease and type 2 diabetes. In the U.S., about 25% of the adult population has metabolic syndrome, a proportion increasing with age, particularly among racial and ethnic minorities.

Insulin resistance, metabolic syndrome, and prediabetes are closely related to one another and have overlapping aspects. The syndrome is thought to be caused by an underlying disorder of energy utilization and storage, but the cause of the syndrome is an area of ongoing medical research. Researchers debate whether a diagnosis of metabolic syndrome implies differential treatment or increases risk of cardiovascular disease beyond what is suggested by the sum of its individual components.

Signs and symptoms

The key sign of metabolic syndrome is central obesity, also known as visceral, male-pattern or apple-shaped adiposity. It is characterized by adipose tissue accumulation predominantly around the waist and trunk. Other signs of metabolic syndrome include high blood pressure, decreased fasting serum HDL cholesterol, elevated fasting serum triglyceride level, impaired fasting glucose, insulin resistance, or prediabetes. Associated conditions include hyperuricemia; fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease; polycystic ovarian syndrome in women and erectile dysfunction in men; and acanthosis nigricans.

Neck circumference

Neck circumference has been used as a surrogate simple and reliable index to indicate upper-body subcutaneous fat accumulation. Neck circumference of more than 40.25 cm (15.85 in) for men and more than 35.75 cm (14.07 in) for women are considered high-risk for metabolic syndrome. Persons with large neck circumferences have a more-than-double risk of metabolic syndrome. In adults with overweight/obesity, clinically significant weight loss may protect against COVID-19 and neck circumference has been associated with the risk of being mechanically ventilated in COVID-19 patients, with a 26% increased risk for each centimeter increase in neck circumference. Moreover, hospitalized COVID-19 patients with a "large neck phenotype" on admission had a more than double risk of death.

Complications

Metabolic syndrome can lead to several serious and chronic complications, including type-2 diabetes, cardiovascular diseases, stroke, kidney disease and nonalcoholic fatty liver disease.

Furthermore, metabolic syndrome is associated with a significantly increased risk of surgical complications across most types of surgery in a 2023 systematic review and meta-analysis of over 13 million individuals.

Causes

The mechanisms of the complex pathways of metabolic syndrome are under investigation. The pathophysiology is very complex and has been only partially elucidated. Most people affected by the condition are older, obese, sedentary, and have a degree of insulin resistance. Stress can also be a contributing factor. The most important risk factors are diet (particularly sugar-sweetened beverage consumption), genetics, aging, sedentary behavior or low physical activity, disrupted chronobiology/sleep, mood disorders/psychotropic medication use, and excessive alcohol use. The pathogenic role played in the syndrome by the excessive expansion of adipose tissue occurring under sustained overeating, and its resulting lipotoxicity was reviewed by Vidal-Puig.

Recent studies have highlighted the global prevalence of metabolic syndrome, driven by the rise in obesity and type 2 diabetes. The World Health Organization (WHO) and other major health organizations define metabolic syndrome with criteria that include central obesity, insulin resistance, hypertension, and dyslipidemia. As of 2015, metabolic syndrome affects approximately 25% of the global population, with rates significantly higher in urban areas due to increased consumption of high-calorie, low-nutrient diets and decreased physical activity. This condition is associated with a threefold increase in the risk of type 2 diabetes and cardiovascular disease, accounting for a substantial burden of non-communicable diseases globally (Saklayen, 2018).

There is debate regarding whether obesity or insulin resistance is the cause of the metabolic syndrome or if they are consequences of a more far-reaching metabolic derangement. Markers of systemic inflammation, including C-reactive protein, are often increased, as are fibrinogen, interleukin 6, tumor necrosis factor-alpha (TNF-α), and others. Some have pointed to a variety of causes, including increased uric acid levels caused by dietary fructose.

Research shows that Western diet habits are a factor in the development of metabolic syndrome, with high consumption of food that is not biochemically suited to humans. Weight gain is associated with metabolic syndrome. Rather than total adiposity, the core clinical component of the syndrome is visceral and/or ectopic fat (i.e., fat in organs not designed for fat storage) whereas the principal metabolic abnormality is insulin resistance. The continuous provision of energy via dietary carbohydrate, lipid, and protein fuels, unmatched by physical activity/energy demand, creates a backlog of the products of mitochondrial oxidation, a process associated with progressive mitochondrial dysfunction and insulin resistance.

Stress

Recent research indicates prolonged chronic stress can contribute to metabolic syndrome by disrupting the hormonal balance of the hypothalamic-pituitary-adrenal axis (HPA-axis). A dysfunctional HPA-axis causes high cortisol levels to circulate, which results in raising glucose and insulin levels, which in turn cause insulin-mediated effects on adipose tissue, ultimately promoting visceral adiposity, insulin resistance, dyslipidemia and hypertension, with direct effects on the bone, causing "low turnover" osteoporosis. HPA-axis dysfunction may explain the reported risk indication of abdominal obesity to cardiovascular disease (CVD), type 2 diabetes and stroke. Psychosocial stress is also linked to heart disease.

Obesity

Central obesity is a key feature of the syndrome, as both a sign and a cause, in that the increasing adiposity often reflected in high waist circumference may both result from and contribute to insulin resistance. However, despite the importance of obesity, affected people who are of normal weight may also be insulin-resistant and have the syndrome.

Sedentary lifestyle

Physical inactivity is a predictor of CVD events and related mortality. Many components of metabolic syndrome are associated with a sedentary lifestyle, including increased adipose tissue (predominantly central); reduced HDL cholesterol; and a trend toward increased triglycerides, blood pressure, and glucose in the genetically susceptible. Compared with individuals who watched television or videos or used their computers for less than one hour daily, those who carried out these behaviors for greater than four hours daily have a twofold increased risk of metabolic syndrome.

Aging

Metabolic syndrome affects 60% of the U.S. population older than age 50. With respect to that demographic, the percentage of women having the syndrome is higher than that of men. The age dependency of the syndrome's prevalence is seen in most populations around the world.

Diabetes mellitus type 2

The metabolic syndrome quintuples the risk of type 2 diabetes mellitus. Type 2 diabetes is considered a complication of metabolic syndrome. In people with impaired glucose tolerance or impaired fasting glucose, presence of metabolic syndrome doubles the risk of developing type 2 diabetes. It is likely that prediabetes and metabolic syndrome denote the same disorder, defining it by the different sets of biological markers.

The presence of metabolic syndrome is associated with a higher prevalence of CVD than found in people with type 2 diabetes or impaired glucose tolerance without the syndrome. Hypoadiponectinemia has been shown to increase insulin resistance and is considered to be a risk factor for developing metabolic syndrome.

Coronary heart disease

The approximate prevalence of the metabolic syndrome in people with coronary artery disease (CAD) is 50%, with a prevalence of 37% in people with premature coronary artery disease (age 45), particularly in women. With appropriate cardiac rehabilitation and changes in lifestyle (e.g., nutrition, physical activity, weight reduction, and, in some cases, drugs), the prevalence of the syndrome can be reduced.

Lipodystrophy

Lipodystrophic disorders in general are associated with metabolic syndrome. Both genetic (e.g., Berardinelli-Seip congenital lipodystrophy, Dunnigan familial partial lipodystrophy) and acquired (e.g., HIV-related lipodystrophy in people treated with highly active antiretroviral therapy) forms of lipodystrophy may give rise to severe insulin resistance and many of metabolic syndrome's components.

Rheumatic diseases

There is research that associates comorbidity with rheumatic diseases. Both psoriasis and psoriatic arthritis have been found to be associated with metabolic syndrome.

Chronic obstructive pulmonary disease

Metabolic syndrome is seen to be a comorbidity in up to 50 percent of those with chronic obstructive pulmonary disease (COPD). It may pre-exist or may be a consequence of the lung pathology of COPD.

Pathophysiology

It is common for there to be a development of visceral fat, after which the adipocytes (fat cells) of the visceral fat increase plasma levels of TNF-α and alter levels of other substances (e.g., adiponectin, resistin, and PAI-1). TNF-α has been shown to cause the production of inflammatory cytokines and also possibly trigger cell signaling by interaction with a TNF-α receptor that may lead to insulin resistance. An experiment with rats fed a diet with 33% sucrose has been proposed as a model for the development of metabolic syndrome. The sucrose first elevated blood levels of triglycerides, which induced visceral fat and ultimately resulted in insulin resistance. The progression from visceral fat to increased TNF-α to insulin resistance has some parallels to human development of metabolic syndrome. The increase in adipose tissue also increases the number of immune cells, which play a role in inflammation. Chronic inflammation contributes to an increased risk of hypertension, atherosclerosis and diabetes.

The involvement of the endocannabinoid system in the development of metabolic syndrome is indisputable. Endocannabinoid overproduction may induce reward system dysfunction and cause executive dysfunctions (e.g., impaired delay discounting), in turn perpetuating unhealthy behaviors. The brain is crucial in development of metabolic syndrome, modulating peripheral carbohydrate and lipid metabolism.

Metabolic syndrome can be induced by overfeeding with sucrose or fructose, particularly concomitantly with high-fat diet. The resulting oversupply of omega-6 fatty acids, particularly arachidonic acid (AA), is an important factor in the pathogenesis of metabolic syndrome. Arachidonic acid (with its precursor – linoleic acid) serves as a substrate to the production of inflammatory mediators known as eicosanoids, whereas the arachidonic acid-containing compound diacylglycerol (DAG) is a precursor to the endocannabinoid 2-arachidonoylglycerol (2-AG) while fatty acid amide hydrolase (FAAH) mediates the metabolism of anandamide into arachidonic acid. Anandamide can also be produced from N-acylphosphatidylethanolamine via several pathways. Anandamide and 2-AG can also be hydrolized into arachidonic acid, potentially leading to increased eicosanoid synthesis.

Diagnosis

NCEP

As of 2023, the U.S. National Cholesterol Education Program Adult Treatment Panel III (2001) continues to be the most widely-used clinical definition. It requires at least three of the following:

• Central obesity: waist circumference ≥ 102 cm or 40 inches (male), ≥ 88 cm or 35 inches(female)
• Dyslipidemia: TG ≥ 1.7 mmol/L (150 mg/dL)
• Dyslipidemia: HDL-C < 40 mg/dL (male), < 50 mg/dL (female)
• Blood pressure ≥ 130/85 mmHg (or treated for hypertension)
• Fasting plasma glucose ≥ 6.1 mmol/L (110 mg/dL)

2009 Interim Joint Statement

The International Diabetes Federation Task Force on Epidemiology and Prevention; the National Heart, Lung, and Blood Institute; the American Heart Association; the World Heart Federation; the International Atherosclerosis Society; and the International Association for the Study of Obesity published an interim joint statement to harmonize the definition of the metabolic syndrome in 2009. According to this statement, the criteria for clinical diagnosis of the metabolic syndrome are three or more of the following:

• Elevated waist circumference with population- and country-specific definitions
• Elevated triglycerides (≥ 150 mg/dL (1.7 mmol/L))
• Reduced HDL-C (≤40 mg/dL (1.0 mmol/L) in males, ≤50 mg/dL (1.3 mmol/L) in females)
• Elevated blood pressure (systolic ≥130 and/or diastolic ≥85 mm Hg)
• Elevated fasting glucose (≥100 mg/dL (5.55 mmol/L)

This definition recognizes that the risk associated with a particular waist measurement will differ in different populations. However, for international comparisons and to facilitate the etiology, the organizations agree that it is critical that a commonly agreed-upon set of criteria be used worldwide, with agreed-upon cut points for different ethnic groups and sexes. There are many people in the world of mixed ethnicity, and in those cases, pragmatic decisions will have to be made. Therefore, an international criterion of overweight may be more appropriate than ethnic specific criteria of abdominal obesity for an anthropometric component of this syndrome which results from an excess lipid storage in adipose tissue, skeletal muscle and liver.

The report notes that previous definitions of the metabolic syndrome by the International Diabetes Federation (IDF) and the revised National Cholesterol Education Program (NCEP) are very similar, and they identify individuals with a given set of symptoms as having metabolic syndrome. There are two differences, however: the IDF definition states that if body mass index (BMI) is greater than 30 kg/m, central obesity can be assumed, and waist circumference does not need to be measured. However, this potentially excludes any subject without increased waist circumference if BMI is less than 30. Conversely, the NCEP definition indicates that metabolic syndrome can be diagnosed based on other criteria. Also, the IDF uses geography-specific cut points for waist circumference, while NCEP uses only one set of cut points for waist circumference regardless of geography.

WHO

The World Health Organization (1999) requires the presence of any one of diabetes mellitus, impaired glucose tolerance, impaired fasting glucose or insulin resistance, AND two of the following:

• Blood pressure ≥ 140/90 mmHg
• Dyslipidemia: triglycerides (TG) ≥ 1.695 mmol/L and HDL cholesterol ≤ 0.9 mmol/L (male), ≤ 1.0 mmol/L (female)
• Central obesity: waist:hip ratio > 0.90 (male); > 0.85 (female), or BMI > 30 kg/m
• Microalbuminuria: urinary albumin excretion ratio ≥ 20 μg/min or albumin:creatinine ratio ≥ 30 mg/g

EGIR

The European Group for the Study of Insulin Resistance (1999) requires that subjects have insulin resistance (defined for purposes of clinical practivality as the top 25% of the fasting insulin values among nondiabetic individuals) AND two or more of the following:

• Central obesity: waist circumference ≥ 94 cm or 37 inches (male), ≥ 80 cm or 31.5 inches (female)
• Dyslipidemia: TG ≥ 2.0 mmol/L (177 mg/dL) and/or HDL-C < 1.0 mmol/L (38.61 mg/dL) or treated for dyslipidemia
• Blood pressure ≥ 140/90 mmHg or antihypertensive medication
• Fasting plasma glucose ≥ 6.1 mmol/L (110 mg/dL)

Cardiometabolic index

The Cardiometabolic index (CMI) is a tool used to calculate risk of type 2 diabetes, non-alcoholic fatty liver disease, and metabolic issues. It is based on calculations from waist-to-height ratio and triglycerides-to-HDL cholesterol ratio.

CMI can also be used for finding connections between cardiovascular disease and erectile dysfunction. When following an anti inflammatory diet (low-glycemic carbohydrates, fruits, vegetables, fish, less red meat and processed foods) the markers may drop resulting in a significant reduction in body weight and adipose tissue.

Other

High-sensitivity C-reactive protein has been developed and used as a marker to predict coronary vascular diseases in metabolic syndrome, and it was recently used as a predictor for nonalcoholic fatty liver disease (steatohepatitis) in correlation with serum markers that indicated lipid and glucose metabolism. Fatty liver disease and steatohepatitis can be considered manifestations of metabolic syndrome, indicative of abnormal energy storage as fat in ectopic distribution. Reproductive disorders (such as polycystic ovary syndrome in women of reproductive age), and erectile dysfunction or decreased total testosterone (low testosterone-binding globulin) in men can be attributed to metabolic syndrome.

Prevention

Various strategies have been proposed to prevent the development of metabolic syndrome. These include increased physical activity (such as walking 30 minutes every day), and a healthy, reduced calorie diet. Many studies support the value of a healthy lifestyle as above. However, one study stated these potentially beneficial measures are effective in only a minority of people, primarily because of a lack of compliance with lifestyle and diet changes. The International Obesity Taskforce states that interventions on a sociopolitical level are required to reduce development of the metabolic syndrome in populations.

The Caerphilly Heart Disease Study followed 2,375 male subjects over 20 years and suggested the daily intake of an Imperial pint (~568 mL) of milk or equivalent dairy products more than halved the risk of metabolic syndrome. Some subsequent studies support the authors' findings, while others dispute them. A systematic review of four randomized controlled trials said that, in the short term, a paleolithic nutritional pattern improved three of five measurable components of the metabolic syndrome in participants with at least one of the components.

Management

This section needs to be updated. Please help update this article to reflect recent events or newly available information. (December 2024)

Diet

Dietary carbohydrate restriction reduces blood glucose levels, contributes to weight loss, and reduces the use of several medications that may be prescribed for metabolic syndrome. Studies suggest that meal timing and frequency can significantly impact the risk of developing metabolic syndrome. Research indicates that individuals who maintain regular meal timings and avoid eating late at night have a reduced risk of developing this condition (Alkhulaifi & Darkoh, 2022).

Medications

Generally, the individual disorders that compose the metabolic syndrome are treated separately. Diuretics and ACE inhibitors may be used to treat hypertension. Various cholesterol medications may be useful if LDL cholesterol, triglycerides, and/or HDL cholesterol is abnormal.

Epidemiology

Approximately 20–25 percent of the world's adult population has the cluster of risk factors that is metabolic syndrome. In 2000, approximately 32% of U.S. adults had metabolic syndrome. In more recent years that figure has climbed to 34%.

In young children, there is no consensus on how to measure metabolic syndrome since age-specific cut points and reference values that would indicate "high risk" have not been well established. A continuous cardiometabolic risk summary score is often used for children instead of a dichotomous measure of metabolic syndrome.

Other conditions and specific microbiome diversity seems to be associated with metabolic syndrome, with certain-degree of gender-specificity.

History

In 1921, Joslin first reported the association of diabetes with hypertension and hyperuricemia. In 1923, Kylin reported additional studies on the above triad. In 1947, Vague observed that upper body obesity appeared to predispose to diabetes, atherosclerosis, gout and calculi. In the late 1950s, the term metabolic syndrome was first used.

In 1967, Avogadro, Crepaldi and coworkers described six moderately obese people with diabetes, hypercholesterolemia, and marked hypertriglyceridemia, all of which improved when the affected people were put on a hypocaloric, low-carbohydrate diet. In 1977, Haller used the term metabolic syndrome for associations of obesity, diabetes mellitus, hyperlipoproteinemia, hyperuricemia, and hepatic steatosis when describing the additive effects of risk factors on atherosclerosis. The same year, Singer used the term for associations of obesity, gout, diabetes mellitus, and hypertension with hyperlipoproteinemia. In 1977 and 1978, Gerald B. Phillips developed the concept that risk factors for myocardial infarction concur to form a "constellation of abnormalities" (i.e., glucose intolerance, hyperinsulinemia, hypercholesterolemia, hypertriglyceridemia, and hypertension) associated not only with heart disease, but also with aging, obesity and other clinical states. He suggested there must be an underlying linking factor, the identification of which could lead to the prevention of cardiovascular disease; he hypothesized that this factor was sex hormones. In 1988, in his Banting lecture, Gerald M. Reaven proposed insulin resistance as the underlying factor and named the constellation of abnormalities syndrome X. Reaven did not include abdominal obesity, which has also been hypothesized as the underlying factor, as part of the condition.

See also

• Metabolic disorder
• Portal-visceral hypothesis

References

1. ^ "Metabolic syndrome". Mayo Clinic. Retrieved 10 Sep 2020.
2. Falkner B, Cossrow ND (July 2014). "Prevalence of metabolic syndrome and obesity-associated hypertension in the racial ethnic minorities of the United States". Current Hypertension Reports. 16 (7): 449. doi:10.1007/s11906-014-0449-5. PMC 4083846. PMID 24819559.
3. Beltrán-Sánchez H, Harhay MO, Harhay MM, McElligott S (August 2013). "Prevalence and trends of metabolic syndrome in the adult U.S. population, 1999–2010". Journal of the American College of Cardiology. 62 (8): 697–703. doi:10.1016/j.jacc.2013.05.064. PMC 3756561. PMID 23810877.
4. ^ Anagnostis, Panagiotis (November 30, 2023). "Metabolic Syndrome". BMJ Best Practice. Retrieved 30 December 2023.
5. "Metabolic Syndrome". Diabetes.co.uk. 15 January 2019.
6. Mendrick DL, Diehl AM, Topor LS, Dietert RR, Will Y, La Merrill MA, et al. (March 2018). "Metabolic Syndrome and Associated Diseases: From the Bench to the Clinic". Toxicological Sciences. 162 (1): 36–42. doi:10.1093/toxsci/kfx233. PMC 6256950. PMID 29106690.
7. Mohseni-Takalloo, Sahar; Mozaffari-Khosravi, Hassan; Mohseni, Hadis; Mirzaei, Masoud; Hosseinzadeh, Mahdieh (2023-06-13). "Evaluating Neck Circumference as an Independent Predictor of Metabolic Syndrome and Its Components Among Adults: A Population-Based Study". Cureus. 15 (6): e40379. doi:10.7759/cureus.40379. ISSN 2168-8184. PMC 10344419. PMID 37456431.
8. Shyam, Sangeetha; García-Gavilán, Jesús Francisco; Paz-Graniel, Indira; Gaforio, José J.; Martínez-González, Miguel Ángel; Corella, Dolores; Martínez, J. Alfredo; Alonso-Gómez, Ángel M.; Wärnberg, Julia; Vioque, Jesús; Romaguera, Dora; López-Miranda, José; Estruch, Ramon; Tinahones, Francisco J.; Lapetra, José (2023-10-13). "Association of adiposity and its changes over time with COVID-19 risk in older adults with overweight/obesity and metabolic syndrome: a longitudinal evaluation in the PREDIMED-Plus cohort". BMC Medicine. 21 (1): 390. doi:10.1186/s12916-023-03079-z. ISSN 1741-7015. PMC 10576302. PMID 37833678.
9. Di Bella, Stefano; Cesareo, Roberto; De Cristofaro, Paolo; Palermo, Andrea; Sanson, Gianfranco; Roman-Pognuz, Erik; Zerbato, Verena; Manfrini, Silvia; Giacomazzi, Donatella; Dal Bo, Eugenia; Sambataro, Gianluca; Macchini, Elisabetta; Quintavalle, Francesco; Campagna, Giuseppe; Masala, Renato (2021). "Neck circumference as reliable predictor of mechanical ventilation support in adult inpatients with COVID-19: A multicentric prospective evaluation". Diabetes/Metabolism Research and Reviews. 37 (1): e3354. doi:10.1002/dmrr.3354. ISSN 1520-7552. PMC 7300447. PMID 32484298.
10. Di Bella, Stefano; Zerbato, Verena; Sanson, Gianfranco; Roman-Pognuz, Erik; De Cristofaro, Paolo; Palermo, Andrea; Valentini, Michael; Gobbo, Ylenia; Jaracz, Anna Wladyslawa; Bozic Hrzica, Elizabeta; Bresani-Salvi, Cristiane Campello; Galindo, Alexandre Bezerra; Crovella, Sergio; Luzzati, Roberto (2021-12-10). "Neck Circumference Predicts Mortality in Hospitalized COVID-19 Patients". Infectious Disease Reports. 13 (4): 1053–60. doi:10.3390/idr13040096. ISSN 2036-7449. PMC 8700782. PMID 34940406.
11. "Metabolic syndrome – Symptoms and causes". Mayo Clinic. Retrieved 2022-03-31.
12. Norris, Philip; Gow, Jeff; Arthur, Thomas; Conway, Aaron; Fleming, Fergal J; Ralph, Nicholas (2 November 2023). "Metabolic syndrome and surgical complications: A systematic review and meta-analysis of 13 million individuals". International Journal of Surgery. 110 (1): 541–53. doi:10.1097/JS9.0000000000000834. PMC 10793842. PMID 37916943.
13. Malik VS, Popkin BM, Bray GA, Després JP, Willett WC, Hu FB (November 2010). "Sugar-sweetened beverages and risk of metabolic syndrome and type 2 diabetes: a meta-analysis". Diabetes Care. 33 (11): 2477–83. doi:10.2337/dc10-1079. PMC 2963518. PMID 20693348.
14. Pollex RL, Hegele RA (September 2006). "Genetic determinants of the metabolic syndrome". Nature Clinical Practice Cardiovascular Medicine. 3 (9): 482–89. doi:10.1038/ncpcardio0638. PMID 16932765. S2CID 24558150.
15. Poulsen P, Vaag A, Kyvik K, Beck-Nielsen H (May 2001). "Genetic versus environmental aetiology of the metabolic syndrome among male and female twins". Diabetologia. 44 (5): 537–43. doi:10.1007/s001250051659. PMID 11380071. S2CID 26582450.
16. Groop L (March 2000). "Genetics of the metabolic syndrome". The British Journal of Nutrition. 83 (Suppl 1): S39–S48. doi:10.1017/S0007114500000945. PMID 10889791. S2CID 8974554.
17. Bouchard C (May 1995). "Genetics and the metabolic syndrome". International Journal of Obesity and Related Metabolic Disorders. 19 (Suppl 1): S52–59. PMID 7550538.
18. Edwardson CL, Gorely T, Davies MJ, Gray LJ, Khunti K, Wilmot EG, Yates T, Biddle SJ (2012). "Association of sedentary behaviour with metabolic syndrome: a meta-analysis". PLOS ONE. 7 (4): e34916. Bibcode:2012PLoSO...734916E. doi:10.1371/journal.pone.0034916. PMC 3325927. PMID 22514690.
19. ^ Katzmarzyk PT, Leon AS, Wilmore JH, Skinner JS, Rao DC, Rankinen T, Bouchard C (October 2003). "Targeting the metabolic syndrome with exercise: evidence from the HERITAGE Family Study". Medicine and Science in Sports and Exercise. 35 (10): 1703–09. doi:10.1249/01.MSS.0000089337.73244.9B. PMID 14523308. S2CID 25598917.
20. He D, Xi B, Xue J, Huai P, Zhang M, Li J (June 2014). "Association between leisure time physical activity and metabolic syndrome: a meta-analysis of prospective cohort studies". Endocrine. 46 (2): 231–40. doi:10.1007/s12020-013-0110-0. PMID 24287790. S2CID 5271746.
21. Xi B, He D, Zhang M, Xue J, Zhou D (August 2014). "Short sleep duration predicts risk of metabolic syndrome: a systematic review and meta-analysis". Sleep Medicine Reviews. 18 (4): 293–97. doi:10.1016/j.smrv.2013.06.001. PMID 23890470.
22. Vancampfort D, Correll CU, Wampers M, Sienaert P, Mitchell AJ, De Herdt A, Probst M, Scheewe TW, De Hert M (July 2014). "Metabolic syndrome and metabolic abnormalities in patients with major depressive disorder: a meta-analysis of prevalences and moderating variables". Psychological Medicine. 44 (10): 2017–28. doi:10.1017/S0033291713002778. PMID 24262678. S2CID 206253750.
23. Vancampfort D, Vansteelandt K, Correll CU, Mitchell AJ, De Herdt A, Sienaert P, Probst M, De Hert M (March 2013). "Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators". The American Journal of Psychiatry. 170 (3): 265–74. doi:10.1176/appi.ajp.2012.12050620. PMID 23361837.
24. Sun K, Ren M, Liu D, Wang C, Yang C, Yan L (August 2014). "Alcohol consumption and risk of metabolic syndrome: a meta-analysis of prospective studies". Clinical Nutrition. 33 (4): 596–602. doi:10.1016/j.clnu.2013.10.003. PMID 24315622.
25. Vidal-Puig A (2013). "Adipose tissue expandability, lipotoxicity and the metabolic syndrome". Endocrinologia y Nutricion. 60 (Suppl 1): 39–43. doi:10.1016/s1575-0922(13)70026-3. PMID 24490226.
26. Saklayen, M.G. (2018). "The Global Epidemic of the Metabolic Syndrome". Current Hypertension Reports. 20 (2): 12. doi:10.1007/s11906-018-0812-z. PMC 5866840. PMID 29480368.
27. Nakagawa T, Hu H, Zharikov S, Tuttle KR, Short RA, Glushakova O, Ouyang X, Feig DI, Block ER, Herrera-Acosta J, Patel JM, Johnson RJ (March 2006). "A causal role for uric acid in fructose-induced metabolic syndrome". American Journal of Physiology. Renal Physiology. 290 (3): F625–31. doi:10.1152/ajprenal.00140.2005. PMID 16234313.
28. Hallfrisch J (June 1990). "Metabolic effects of dietary fructose". FASEB Journal. 4 (9): 2652–60. doi:10.1096/fasebj.4.9.2189777. PMID 2189777. S2CID 23659634.
29. Reiser S, Powell AS, Scholfield DJ, Panda P, Ellwood KC, Canary JJ (May 1989). "Blood lipids, lipoproteins, apoproteins, and uric acid in men fed diets containing fructose or high-amylose cornstarch". The American Journal of Clinical Nutrition. 49 (5): 832–39. doi:10.1093/ajcn/49.5.832. PMID 2497634.
30. Bremer AA, Mietus-Snyder M, Lustig RH (March 2012). "Toward a unifying hypothesis of metabolic syndrome". Pediatrics. 129 (3): 557–70. doi:10.1542/peds.2011-2912. PMC 3289531. PMID 22351884.
31. Ali ES, Hua J, Wilson CH, Tallis GA, Zhou FH, Rychkov GY, Barritt GJ (September 2016). "The glucagon-like peptide-1 analogue exendin-4 reverses impaired intracellular Ca(2+) signalling in steatotic hepatocytes". Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 1863 (9): 2135–46. doi:10.1016/j.bbamcr.2016.05.006. PMID 27178543.
32. Gohil BC, Rosenblum LA, Coplan JD, Kral JG (July 2001). "Hypothalamic-pituitary-adrenal axis function and the metabolic syndrome X of obesity". CNS Spectrums. 6 (7): 581–86, 589. doi:10.1017/s1092852900002121. PMID 15573024. S2CID 22734016.
33. Tsigos C, Chrousos GP (October 2002). "Hypothalamic-pituitary-adrenal axis, neuroendocrine factors and stress". Journal of Psychosomatic Research. 53 (4): 865–71. doi:10.1016/S0022-3999(02)00429-4. PMID 12377295.
34. Rosmond R, Björntorp P (February 2000). "The hypothalamic-pituitary-adrenal axis activity as a predictor of cardiovascular disease, type 2 diabetes and stroke". Journal of Internal Medicine. 247 (2): 188–97. doi:10.1046/j.1365-2796.2000.00603.x. PMID 10692081. S2CID 20336259.
35. Brunner EJ, Hemingway H, Walker BR, Page M, Clarke P, Juneja M, Shipley MJ, Kumari M, Andrew R, Seckl JR, Papadopoulos A, Checkley S, Rumley A, Lowe GD, Stansfeld SA, Marmot MG (November 2002). "Adrenocortical, autonomic, and inflammatory causes of the metabolic syndrome: nested case-control study". Circulation. 106 (21): 2659–65. doi:10.1161/01.cir.0000038364.26310.bd. PMID 12438290. S2CID 5992769.
36. ^ Fauci, Anthony S. (2008). Harrison's principles of internal medicine. McGraw-Hill Medical. ISBN 978-0-07-147692-8.
37. Goldberg RB, Mather K (September 2012). "Targeting the consequences of the metabolic syndrome in the Diabetes Prevention Program". Arteriosclerosis, Thrombosis, and Vascular Biology. 32 (9): 2077–90. doi:10.1161/ATVBAHA.111.241893. PMC 3901161. PMID 22895669.
38. Lara-Castro C, Fu Y, Chung BH, Garvey WT (June 2007). "Adiponectin and the metabolic syndrome: mechanisms mediating risk for metabolic and cardiovascular disease". Current Opinion in Lipidology. 18 (3): 263–70. doi:10.1097/MOL.0b013e32814a645f. PMID 17495599. S2CID 20799218.
39. Renaldi O, Pramono B, Sinorita H, Purnomo LB, Asdie RH, Asdie AH (January 2009). "Hypoadiponectinemia: a risk factor for metabolic syndrome". Acta Medica Indonesiana. 41 (1): 20–24. PMID 19258676.
40. Quilon III A, Brent L (2010). "The primary care physician's guide to inflammatory arthritis: diagnosis". The Journal of Musculoskeletal Medicine. 27: 223–31.
41. Chan SM, Selemidis S, Bozinovski S, Vlahos R (June 2019). "Pathobiological mechanisms underlying metabolic syndrome (MetS) in chronic obstructive pulmonary disease (COPD): clinical significance and therapeutic strategies". Pharmacol Ther. 198: 160–88. doi:10.1016/j.pharmthera.2019.02.013. PMC 7112632. PMID 30822464.
42. Hotamisligil GS (June 1999). "The role of TNFalpha and TNF receptors in obesity and insulin resistance". Journal of Internal Medicine. 245 (6): 621–25. doi:10.1046/j.1365-2796.1999.00490.x. PMID 10395191. S2CID 58332116.
43. Whitney, Ellie and Ralfes, R. Sharon. 2011. Understanding Nutrition. Wadsworth Cengage Learning: Belmont, CA
44. ^ Gatta-Cherifi B, Cota D (2015). "Endocannabinoids and Metabolic Disorders". Endocannabinoids. Handbook of Experimental Pharmacology. Vol. 231. pp. 367–91. doi:10.1007/978-3-319-20825-1_13. ISBN 978-3-319-20824-4. PMID 26408168. The endocannabinoid system (ECS) is known to exert regulatory control on essentially every aspect related to the search for, and the intake, metabolism and storage of calories, and consequently it represents a potential pharmacotherapeutic target for obesity, diabetes and eating disorders. ... recent research in animals and humans has provided new knowledge on the mechanisms of actions of the ECS in the regulation of eating behavior, energy balance, and metabolism. In this review, we discuss these recent advances and how they may allow targeting the ECS in a more specific and selective manner for the future development of therapies against obesity, metabolic syndrome, and eating disorders.
45. ^ Vemuri VK, Janero DR, Makriyannis A (March 2008). "Pharmacotherapeutic targeting of the endocannabinoid signaling system: drugs for obesity and the metabolic syndrome". Physiology & Behavior. 93 (4–5): 671–86. doi:10.1016/j.physbeh.2007.11.012. PMC 3681125. PMID 18155257. The etiology of many appetitive disorders is characterized by a pathogenic component of reward-supported craving, be it for substances of abuse (including alcohol and nicotine) or food. Such maladies affect large numbers of people as prevalent socioeconomic and healthcare burdens. Yet in most instances drugs for their safe and effective pharmacotherapeutic management are lacking despite the attendant medical needs, collateral adverse physical and psychological effects, and enormous global market potential. The endocannabinoid signaling system plays a critical role in motivational homeostasis as a conduit for reward stimuli and a positive modulator of brain reward circuits. Endocannabinoid-system hyperactivity through CB1 receptor transmission is considered contributory to a range of appetitive disorders and, hence, is a major focus of contemporary pharmaceutical research.
46. ^ Turcotte C, Chouinard F, Lefebvre JS, Flamand N (June 2015). "Regulation of inflammation by cannabinoids, the endocannabinoids 2-arachidonoyl-glycerol and arachidonoyl-ethanolamide, and their metabolites". Journal of Leukocyte Biology. 97 (6): 1049–70. doi:10.1189/jlb.3RU0115-021R. PMID 25877930. S2CID 206999921.
47. Fukuchi S, Hamaguchi K, Seike M, Himeno K, Sakata T, Yoshimatsu H (June 2004). "Role of fatty acid composition in the development of metabolic disorders in sucrose-induced obese rats". Experimental Biology and Medicine. 229 (6): 486–93. doi:10.1177/153537020422900606. PMID 15169967. S2CID 20966659.
48. Di Marzo V, Fontana A, Cadas H, et al. (Dec 1994). "Formation and inactivation of endogenous cannabinoid anandamide in central neurons". Nature (Submitted manuscript). 372 (6507): 686–91. Bibcode:1994Natur.372..686D. doi:10.1038/372686a0. PMID 7990962. S2CID 4341716.
49. Expert Panel On Detection, Evaluation (May 2001). "Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults". JAMA. 285 (19): 2486–97. doi:10.1001/jama.285.19.2486. PMID 11368702.
50. ^ Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC (October 2009). "Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity" (PDF). Circulation. 120 (16): 1640–45. doi:10.1161/CIRCULATIONAHA.109.192644. PMID 19805654.
51. ^ Alberti G, Zimmet P, Shaw J (2006). Grundy SM (ed.). IDF Consensus Worldwide Definition of the Metabolic Syndrome (PDF) (Report). Brussels, Belgium: International Diabetes Federation. Archived from the original on 2012-09-16.
52. Alberti KG, et al. (1999). "Definition, Diagnosis, and Classification of Diabetes Mellitus and its Complications" (PDF). World Health Organization. pp. 32–33. Archived from the original (PDF) on 21 August 2014. Retrieved 25 March 2013.
53. Balkau B, Charles MA (May 1999). "Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR)". Diabet Med. 16 (5): 442–43. doi:10.1046/j.1464-5491.1999.00059.x. PMID 10342346.
54. Khanmohammadi, Shaghayegh; Tavolinejad, Hamed; Aminorroaya, Arya; Rezaie, Yasaman; Ashraf, Haleh; Vasheghani-Farahani, Ali (2022-08-30). "Association of lipid accumulation product with type 2 diabetes mellitus, hypertension, and mortality: a systematic review and meta-analysis". Journal of Diabetes & Metabolic Disorders. 21 (2). Springer Science and Business Media LLC: 1943–73. doi:10.1007/s40200-022-01114-z. ISSN 2251-6581. PMC 9672205. PMID 36404835. S2CID 251912707.
55. Pluta, Waldemar; Dudzińska, Wioleta; Lubkowska, Anna (2022-01-06). "Metabolic Obesity in People with Normal Body Weight (MONW) – Review of Diagnostic Criteria". International Journal of Environmental Research and Public Health. 19 (2). MDPI AG: 624. doi:10.3390/ijerph19020624. ISSN 1660-4601. PMC 8776153. PMID 35055447.
56. Chen, Lei; Shi, Guang-rui; Huang, Dan-dan; Li, Yang; Ma, Chen-chao; Shi, Min; Su, Bin-xiao; Shi, Guang-jiang (2019). "Male sexual dysfunction: A review of literature on its pathological mechanisms, potential risk factors, and herbal drug intervention". Biomedicine & Pharmacotherapy. 112. Elsevier BV: 108585. doi:10.1016/j.biopha.2019.01.046. ISSN 0753-3322. PMID 30798136.
57. Bagheri, Soghra; Zolghadri, Samaneh; Stanek, Agata (2022-09-26). "Beneficial Effects of Anti-Inflammatory Diet in Modulating Gut Microbiota and Controlling Obesity". Nutrients. 14 (19). MDPI AG: 3985. doi:10.3390/nu14193985. ISSN 2072-6643. PMC 9572805. PMID 36235638.
58. Kogiso T, Moriyoshi Y, Shimizu S, Nagahara H, Shiratori K (2009). "High-sensitivity C-reactive protein as a serum predictor of nonalcoholic fatty liver disease based on the Akaike Information Criterion scoring system in the general Japanese population". Journal of Gastroenterology. 44 (4): 313–21. doi:10.1007/s00535-009-0002-5. PMID 19271113. S2CID 1193178.
59. Brand JS, van der Tweel I, Grobbee DE, Emmelot-Vonk MH, van der Schouw YT (February 2011). "Testosterone, sex hormone-binding globulin and the metabolic syndrome: a systematic review and meta-analysis of observational studies". International Journal of Epidemiology. 40 (1): 189–207. doi:10.1093/ije/dyq158. PMID 20870782.
60. Lakka TA, Laaksonen DE (February 2007). "Physical activity in prevention and treatment of the metabolic syndrome". Applied Physiology, Nutrition, and Metabolism. 32 (1): 76–88. doi:10.1139/h06-113. PMID 17332786.
61. Feldeisen SE, Tucker KL (February 2007). "Nutritional strategies in the prevention and treatment of metabolic syndrome". Applied Physiology, Nutrition, and Metabolism. 32 (1): 46–60. doi:10.1139/h06-101. PMID 17332784.
62. James PT, Rigby N, Leach R (February 2004). "The obesity epidemic, metabolic syndrome and future prevention strategies". European Journal of Cardiovascular Prevention and Rehabilitation. 11 (1): 3–8. doi:10.1097/01.hjr.0000114707.27531.48. PMID 15167200. S2CID 36797932.
63. Elwood PC, Pickering JE, Fehily AM (August 2007). "Milk and dairy consumption, diabetes and the metabolic syndrome: the Caerphilly prospective study". Journal of Epidemiology and Community Health. 61 (8): 695–98. doi:10.1136/jech.2006.053157. PMC 2652996. PMID 17630368.
64. Snijder MB, van der Heijden AA, van Dam RM, Stehouwer CD, Hiddink GJ, Nijpels G, Heine RJ, Bouter LM, Dekker JM (April 2007). "Is higher dairy consumption associated with lower body weight and fewer metabolic disturbances? The Hoorn Study". The American Journal of Clinical Nutrition. 85 (4): 989–95. doi:10.1093/ajcn/85.4.989. PMID 17413097.
65. Manheimer EW, van Zuuren EJ, Fedorowicz Z, Pijl H (October 2015). "Paleolithic nutrition for metabolic syndrome: systematic review and meta-analysis". The American Journal of Clinical Nutrition. 102 (4): 922–32. doi:10.3945/ajcn.115.113613. PMC 4588744. PMID 26269362.
66. Feinman RD, Pogozelski WK, Astrup A, Bernstein RK, Fine EJ, Westman EC, et al. (January 2015). "Dietary carbohydrate restriction as the first approach in diabetes management: critical review and evidence base". Nutrition. 31 (1): 1–13. doi:10.1016/j.nut.2014.06.011. PMID 25287761.
67. Alkhulaifi, F. (2022). "Meal Timing, Meal Frequency and Metabolic Syndrome". Nutrients. 14 (1719): 1719. doi:10.3390/nu14091719. PMC 9102985. PMID 35565686.
68. Srikanthan K, Feyh A, Visweshwar H, Shapiro JI, Sodhi K (2016). "Systematic Review of Metabolic Syndrome Biomarkers: A Panel for Early Detection, Management, and Risk Stratification in the West Virginian Population". International Journal of Medical Sciences. 13 (1): 25–38. doi:10.7150/ijms.13800. PMC 4716817. PMID 26816492.
69. Ford ES, Li C, Zhao G (September 2010). "Prevalence and correlates of metabolic syndrome based on a harmonious definition among adults in the US". Journal of Diabetes. 2 (3): 180–93. doi:10.1111/j.1753-0407.2010.00078.x. PMID 20923483. S2CID 5145131.
70. ^ Ford ES, Giles WH, Mokdad AH (October 2004). "Increasing prevalence of the metabolic syndrome among u.s. Adults". Diabetes Care. 27 (10): 2444–49. doi:10.2337/diacare.27.10.2444. PMID 15451914.
71. Mozumdar A, Liguori G (January 2011). "Persistent increase of prevalence of metabolic syndrome among U.S. adults: NHANES III to NHANES 1999–2006". Diabetes Care. 34 (1): 216–19. doi:10.2337/dc10-0879. PMC 3005489. PMID 20889854.
72. Kamel M, Smith BT, Wahi G, Carsley S, Birken CS, Anderson LN (December 2018). "Continuous cardiometabolic risk score definitions in early childhood: a scoping review". Obesity Reviews. 19 (12): 1688–99. doi:10.1111/obr.12748. PMID 30223304. S2CID 52291692.
73. Chiarelli F, Mohn A (October 2017). "Early diagnosis of metabolic syndrome in children". The Lancet. Child & Adolescent Health. 1 (2): 86–88. doi:10.1016/S2352-4642(17)30043-3. PMID 30169210.
74. Mendrick, Donna L; Diehl, Anna Mae; Topor, Lisa S; Dietert, Rodney R; Will, Yvonne; La Merrill, Michele A; Bouret, Sebastien; Varma, Vijayalaskshmi; Hastings, Kenneth L; Schug, Thaddeus T; Emeigh Hart, Susan G; Burleson, Florence G (2018-03-01). "Metabolic Syndrome and Associated Diseases: From the Bench to the Clinic". Toxicological Sciences. 162 (1): 36–42. doi:10.1093/toxsci/kfx233. ISSN 1096-6080. PMC 6256950. PMID 29106690.
75. Fan, Yong; Pedersen, Oluf (January 2021). "Gut microbiota in human metabolic health and disease". Nature Reviews Microbiology. 19 (1): 55–71. doi:10.1038/s41579-020-0433-9. ISSN 1740-1526. PMID 32887946. S2CID 256744684.
76. Pietropaoli, Davide; Altamura, Serena; Ortu, Eleonora; Guerrini, Luca; Pizarro, Theresa T.; Ferri, Claudio; Del Pinto, Rita (2023-04-10). "Association between metabolic syndrome components and gingival bleeding is women-specific: a nested cross-sectional study". Journal of Translational Medicine. 21 (1): 252. doi:10.1186/s12967-023-04072-z. ISSN 1479-5876. PMC 10088168. PMID 37038173.
77. Joslin E (1921). "The Prevention of Diabetes Mellitus". JAMA. 76 (2): 79–84. doi:10.1001/jama.1921.02630020001001.
78. Kylin E (1923). "". Zentralbl Inn Med (in German). 44: 105–27.
79. Vague J (1947). "La diffférenciacion sexuelle, facteur déterminant des formes de l'obésité". Presse Med. 30: 339–40.
80. Avogaro P, Crepaldi G, Enzi G, Tiengo A (1967). "Associazione di iperlipemia, diabete mellito e obesita' di medio grado" [Association of hyperlipemia, diabetes mellitus and middle-degree obesity]. Acta Diabetologica Latina (in Italian). 4 (4): 572–90. doi:10.1007/BF01544100. S2CID 25839940.
81. Haller H (April 1977). "". Zeitschrift für Sie Gesamte Innere Medizin und Ihre Grenzgebiete. 32 (8): 124–28. PMID 883354.
82. Singer P (May 1977). "". Zeitschrift für die Gesamte Innere Medizin und Ihre Grenzgebiete. 32 (9): 129–33. PMID 906591.
83. Phillips GB (July 1978). "Sex hormones, risk factors and cardiovascular disease". The American Journal of Medicine. 65 (1): 7–11. doi:10.1016/0002-9343(78)90685-X. PMID 356599.
84. Phillips GB (April 1977). "Relationship between serum sex hormones and glucose, insulin and lipid abnormalities in men with myocardial infarction". Proceedings of the National Academy of Sciences of the United States of America. 74 (4): 1729–33. Bibcode:1977PNAS...74.1729P. doi:10.1073/pnas.74.4.1729. PMC 430867. PMID 193114.
85. Reaven GM (December 1988). "Banting lecture 1989. Role of insulin resistance in human disease". Diabetes. 37 (12): 1595–607. doi:10.2337/diabetes.37.12.1595. PMID 3056758.

• Metabolic disorders
• Endocrine diseases
• Medical conditions related to obesity
• Syndromes affecting the endocrine system
• Syndromes with obesity